IRB #

STUDY00021998

Title

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

Principal Investigator

Shivaani Kummar

Study Purpose

The purpose of this study is to find out if the investigational drug called PC14586 is safe in people with cancers that have a specific mutation and what effects it has on that cancer.

Medical Condition(s)

advanced cancer with a specific mutation on the p53 gene

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Diagnosed with advanced or metastatic cancer that has the p53 mutation.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.

If your cancer improves or stays the same and you do not have serious side effects from the study drug, you may remain in the study as long as your study doctor feels you may benefit. However, you are free to stop taking part in this study at any time and for any reason.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

PMV Pharmaceuticals, Inc.

Recruitment End

03/01/2022

Compensation Provided

No


Go Back